Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-6209 Plus Letrozole as First-line Therapy in Advanced or Metastatic Breast Cancer
NCT07894328Phase 3Not yet recruiting
- Sponsor
- Hengrui
- Start
- Nov 2026
- Primary completion
- Jul 2031
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-6209 in breast cancer, sponsored by Hengrui. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
HRS-6209
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07894328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07894328.